Valia Karantza retweeted
What an incredible #SABCS23! A special thanks to the superstar @VKaklamani for all are hard work!
Valia Karantza retweeted
#SABCS23 recap: New Drug Approvals for Metastatic Breast Cancer. Featuring @lalehamiri; Martine Piccart, MD, PhD; @VKaklamani; Flora Mulkey, MS; @KarantzaValia; @JaniceTNBCmets; Mirat Shah, MD; @pre_ryan; Aarón Sosa Mejia, MD; & Christy Osgood, MD.
bit.ly/3TguaBx
#BCSM
Valia Karantza retweeted
Congrats @dradityabardia!!! Wonderful work!
Congratulations to @dradityabardia, recipient of the Massachusetts Society of Clinical Oncology's Distinguished Researcher Award! So proud of him and our @MGHCancerCenter team!
Valia Karantza retweeted
ESMO announced the recipients of the 2022 ESMO Society Awards. These four prestigious distinctions recognise the work and dedication they have put into improving the field of oncology.
👉ow.ly/gUj450K24fE
Valia Karantza retweeted
Nobel Prize in Physiology or Medicine was awarded jointly on Monday to David Julius and Ardem Patapoutian for their discoveries of receptors for temperature and touch. Hot off the press @nytimes nytimes.com/2021/10/04/healt…
Valia Karantza retweeted
Exciting times! – at Paris, France
Practice-changing results in HER2+ MBC
👉 T-DXd beats T-DM1 in 2L: impressive gain in PFS and new SoC
💡Translational research to better understand such difference and help development in other settings/tumors
👏 @JavierCortesMD @curijoey @ErikaHamilton9 and all investigators
Valia Karantza retweeted
I'm thrilled with the news that @stolaney1 will be soon the new Chief of the Division of Breast Oncology @DanaFarber You are an inspiration, a very kind person and a generous mentor. Congrats and success on your new role. All the best 😉
Valia Karantza retweeted
Είμαι ευτυχισμένος με αυτό το αποτέλεσμα !
Πρώτα για όσα πέρασα τα τελευταία χρόνια και βρίσκομαι σήμερα εδώ και ύστερα γιατί μου δίνει κίνητρο αυτό το αποτέλεσμα να συνεχίζω να γίνομαι καλύτερος !
Η κορυφή μας ανήκει !
Ευχαριστώ Ελλάδα 🇬🇷🇬🇷
#Tokyo2020 #hellas #petrounias
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment merck.com/news/fda-approves-…
Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10) - Merck.com merck.com/news/merck-announc…
Valia Karantza retweeted
It is time for the #Tokyo2020 Parade of Athletes 👋
As is custom, Greece🇬🇷 are the first nation to enter the Olympic Stadium at the #OpeningCeremony
#UnitedByEmotion | #StrongerTogether | #Olympics
Valia Karantza retweeted
One day to go 🔔 #ESMOVirtualPlenary: Don’t miss this opportunity to discover the latest data in #TNBC and submit your questions to top experts in #oncology 👉 ow.ly/lIGR50Fu61U
@FAndreMD @curijoey @LoiSher @DrLisaCarey #Breastcancer #bcsm
Valia Karantza retweeted
do not miss the presentation of our study at ESMO Virtual Plenaries - July 2021 @myESMO esmo.org/meetings/keynote-52…
Valia Karantza retweeted
Important data from KN522 to be presented 7/15 and 7/16 as part of the ESMO Virtual Plenary
@myESMO #bcsm
Does the addition of #pembrolizumab to neoadjuvant #chemotherapy improve event-free survival in women with early #TNBC? Join us on 15 & 16 July to discover the latest data in TNBC
👉 More details: ow.ly/LuLA50Fie7H #bcsm @FAndreMD @curijoey @LoiSher @DrLisaCarey #bcsm
Valia Karantza retweeted
It’s the first time in major history that two Greek players are in the Grand Slam semifinals. 🇬🇷
Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) - Merck.com merck.com/news/merck-announc…
The World Turns Greek on March 25 to Mark Greece’s Bicentennial greekreporter.com/2021/03/21… via @greekreporter






























